CytomX Therapeutics, Inc.
CTMXNASDAQHealthcare● Active
$2.93
$-0.08(-2.50%)
Market Cap$470408822
P/E Ratio—
52W High$8.21
52W Low$1.72
CytomX Therapeutics, Inc. (CTMX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTMX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $68.73M | $83.38M | $77.68M | $111.65M | $114.19M |
| G&A Expenses | $29.84M | $29.73M | $30.02M | $42.85M | $39.16M |
| Total Operating Expenses | $98.56M | $113.11M | $107.70M | $154.50M | $153.35M |
| Operating Income | ($22.36M) | $25.00M | ($6.48M) | ($101.33M) | ($116.04M) |
| Operating Margin %(computed) | -29.35% | 18.10% | -6.41% | -190.61% | -311.00% |
| Interest Income | $5.21M | $7.14M | $9.84M | $1.68M | $0.26M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($17.13M) | $32.09M | $3.32M | ($99.32M) | ($115.87M) |
| Income Tax Expense | $0.24M | $0.22M | $3.89M | $0.00M | $0.00M |
| Net Income | ($17.37M) | $31.87M | ($0.57M) | ($99.32M) | ($115.87M) |
| Net Margin %(computed) | -22.79% | 23.08% | -0.56% | -186.82% | -310.54% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.15 | $0.38 | $-0.01 | $-1.48 | $-1.26 |
| Wtd Avg Shares | 137.94M | 84.44M | 73.81M | 65.74M | 64.15M |
| EBITDA | ($20.99M) | $26.76M | ($4.31M) | ($98.89M) | ($113.34M) |
| EBITDA Margin %(computed) | -27.54% | 19.38% | -4.26% | -186.02% | -303.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more CytomX Therapeutics, Inc. data
About CytomX Therapeutics, Inc. (CTMX) Income Statement
CytomX Therapeutics, Inc. (CTMX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CTMX reported revenue of $0.08B, gross profit of $0.08B (gross margin 100.00%), and net income of ($0.02B) — a net profit margin of -22.79%.
Frequently asked questions
CTMX · 4 questionsCytomX Therapeutics, Inc. (CTMX) reported revenue of $0.08B for 2025, down 44.8% year-over-year.
CTMX revenueCTMX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08